Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China : Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization.
BMC Ophthalmol
; 21(1): 116, 2021 Mar 04.
Article
em En
| MEDLINE
| ID: mdl-33663431
ABSTRACT
BACKGROUND:
To evaluate the 12-month efficacy and safety of intravitreal conbercept for myopic choroidal neovascularization (CNV).METHODS:
A retrospective, observational study. Thirty-four eyes of 34 pathologic myopic patients with CNV were treated with intravitreal conbercept (IVC) 0.5 mg with a follow up of 12 months. After the first injection, administration of conbercept followed a pro re nata (PRN) regimen. Outcomes included best corrected visual acuity (BCVA), central retinal thickness (CRT), CNV size, the total number of treatments, and adverse events.RESULTS:
The mean patient age was 55.88 ± 16.17 years, and the mean eye spherical equivalent was - 8.72 ± 3.75 D. The mean number of IVC over 12 months was 2.12 ± 0.69. Overall, best-corrected visual acuity(BCVA)improved from 0.86 ± 0.33 logMAR at baseline to 0.44 ± 0.32 logMAR at month 12 (p < 0.001), mean improvement of vision was 4.12 ± 2.69 lines. Mean central retinal thickness reduced from 285.9 ± 104.6 µm at baseline to 192.1 ± 97.5 µm at month 12 (p < 0.001). Mean CNV size decreased from 0.52 ± 0.38 mm2 at baseline to 0.31 ± 0.19 mm2 at 12 months (p < 0.05). All the 34 eyes had reduced or stable size of CNV. Thirty-two eyes (94.12 %) showed the absence of CNV leakage at the end of the study period. No severe systemic or ocular adverse events were observed.CONCLUSIONS:
Intravitreal conbercept 0.5 mg was safe and effective for treatment of myopic CNV over 12 months in a real-world setting.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neovascularização de Coroide
/
Miopia Degenerativa
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article